A versatile system for rapid multiplex genome-edited CAR T cell generation

June, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

June, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73

June, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Rheingold, 2013, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507

Tschernia, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Wasielewska, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38

Salonga, 2010, PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis, Hum Genet, 127, 411, 10.1007/s00439-009-0781-z

Brochez, 2015, Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma, Oncoimmunology, 4, e982382, 10.4161/2162402X.2014.982382

Quax, 2013, T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development, Int J Cardiol, 168, 1965, 10.1016/j.ijcard.2012.12.085

Anderson, 2013, TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer, Oncoimmunology, 2, e23849, 10.4161/onci.23849

Smyth, 2011, Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors, Cancer Res, 71, 3540, 10.1158/0008-5472.CAN-11-0096

Smyth, 2011, Prospects for TIM3-Targeted Antitumor Immunotherapy, Cancer Res, 71, 6567, 10.1158/0008-5472.CAN-11-1487

Odunsi, 2015, LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model, Oncotarget, 6, 27359, 10.18632/oncotarget.4751

Casorati, 2012, Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer, Nat Med, 18, 807, 10.1038/nm.2700

Bonini, 2012, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 119, 5697, 10.1182/blood-2012-01-405365

Liu, 1997, Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotropic virus type I Tax transactivator, J Gen Virol, 78, 3277, 10.1099/0022-1317-78-12-3277

Wang, 1993, Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide, Proc Natl Acad Sci U S A, 90, 4409, 10.1073/pnas.90.10.4409

Mullbacher, 1999, Cell death induced by the Fas/Fas ligand pathway and its role in pathology, Immunol Cell Biol, 77, 312, 10.1046/j.1440-1711.1999.00837.x

Noble, 2001, Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha, J Leukoc Biol, 70, 756, 10.1189/jlb.70.5.756

Bouchier-Hayes, 2002, Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack, Immunol Cell Biol, 80, 131, 10.1046/j.1440-1711.2002.01068.x

De Benedetti, 2001, Activation-induced cell death and Fas-induced apoptosis in patients with systemic or pauciarticular juvenile idiopathic arthritis, Clin Exp Rheumatol, 19, 339

Jensen, 2015, Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD, Cancer Immunol Res, 3, 368, 10.1158/2326-6066.CIR-14-0200

Zhang, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143

Church, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033

Doudna, 2010, Sequence- and structure-specific RNA processing by a CRISPR endonuclease, Science, 329, 1355, 10.1126/science.1192272

Zhao, 2016, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin Cancer Res

Zhang, 2016, Rationally engineered Cas9 nucleases with improved specificity, Science, 351, 84, 10.1126/science.aad5227

van Steensel, 2014, Easy quantitative assessment of genome editing by sequence trace decomposition, Nucleic Acids Res, 42, e168, 10.1093/nar/gku936

Ventura, 2015, Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries, Nat Commun, 6, 8083, 10.1038/ncomms9083

Tager, 2014, Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9, Cell Stem Cell, 15, 643, 10.1016/j.stem.2014.10.004

Hu, 2015, Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9, J Gen Virol, 96, 2381, 10.1099/vir.0.000139

Zhou, 2014, CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection, PLoS One, 9, e115987, 10.1371/journal.pone.0115987

Marson, 2015, Generation of knock-in primary human T cells using Cas9 ribonucleoproteins, Proc Natl Acad Sci U S A, 112, 10437, 10.1073/pnas.1512503112

Dellinger, 2015, Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells, Nat Biotechnol, 33, 985, 10.1038/nbt.3290

Cheung, 2015, Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies, Cancer Res, 75, 3853, 10.1158/0008-5472.CAN-14-3321

Zhang, 2016, Rationally engineered Cas9 nucleases with improved specificity, Science, 351, 84, 10.1126/science.aad5227

Joung, 2016, High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects, Nature, 529, 490, 10.1038/nature16526